Meeting
2022 ASCO Annual Meeting
A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and non–small cell lung cancer (NSCLC; IMP-MEL).
Authors
Nicholas Coupe
Oxford University Hospital, Oxford, United Kingdom
Nicholas Coupe , Ian B. Walters , Robert A. Kramer , Uzi Gileadi , Mark R. Middleton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
80472712
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2582)
DOI
10.1200/JCO.2022.40.16_suppl.2582
Abstract #
2582
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).
First Author: Nicholas Coupe
Poster
2023 ASCO Annual Meeting
A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.
First Author: Jordi Rodon Ahnert
Poster
2020 ASCO Virtual Scientific Program
Randomized phase II study of canakinumab (CAN) or pembrolizumab (PEM) as monotherapy or in combination as neoadjuvant therapy in patients (Pts) with surgically resected (Stage IB-IIIA) non-small cell lung cancer (NSCLC): CANOPY-N.
First Author: Tony S. K. Mok
Poster
2019 ASCO Annual Meeting
A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).
First Author: Julio Antonio Peguero